(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Jump to: navigation, search


Beta-CIT.png
(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane
Systematic (IUPAC) name
methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl -8-azabicyclo[3.2.1]octane-2-carboxylate
Identifiers
CAS number 133647-95-7
ATC code  ?
PubChem 108220
Chemical data
Formula C16H20INO2 
Mol. mass 385.24 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Legal

Routes  ?

WikiDoc Resources for (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Articles

Most recent articles on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Most cited articles on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Review articles on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Articles on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Images of (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Photos of (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Podcasts & MP3s on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Videos on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Evidence Based Medicine

Cochrane Collaboration on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Bandolier on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

TRIP on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Clinical Trials

Ongoing Trials on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane at Clinical Trials.gov

Trial results on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Clinical Trials on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

NICE Guidance on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

NHS PRODIGY Guidance

FDA on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

CDC on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Books

Books on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

News

(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane in the news

Be alerted to news on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

News trends on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Commentary

Blogs on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Definitions

Definitions of (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Patient Resources / Community

Patient resources on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Discussion groups on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Patient Handouts on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Directions to Hospitals Treating (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Risk calculators and risk factors for (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Healthcare Provider Resources

Symptoms of (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Causes & Risk Factors for (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Diagnostic studies for (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Treatment of (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Continuing Medical Education (CME)

CME Programs on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

International

(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane en Espanol

(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane en Francais

Business

(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane in the Marketplace

Patents on (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

Experimental / Informatics

List of terms related to (-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane

(-)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT or RTI-55) is a stimulant drug used in scientific research and with some medical uses, which was developed in the early 1990s.[1] β-CIT is a phenyltropane based dopamine reuptake inhibitor and is derived from methylecgonidine. β-CIT is one of the most potent phenyltropane stimulants that is commercially available, which limits its use in humans, as it might have significant abuse potential if used outside of a strictly controlled medical setting.[2] When radiolabeled with iodine-123, it is known as iometopane.

Uses

β-CIT is mainly used in scientific research into the dopamine reuptake transporter. Various radiolabelled forms of β-CIT (with different radioactive isotopes of iodine used depending on the application) are used in both humans and animals to map the distribution of dopamine transporters and serotonin transporters in the brain.[3][4] The main practical application for this drug in medicine is to assess the rate of dopamine neuron degradation in the brains of sufferers of Parkinson's disease[5][6] and some other conditions such as progressive supranuclear palsy.[7]

Legal Status

β-CIT is legal in all countries throughout the world as of 2007. Some jurisdictions such as the USA, Canada, Australia and New Zealand might however consider β-CIT to be a controlled substance analogue of cocaine on the grounds of its related chemical structure.

References

  1. Boja JW, Patel A, Carroll FI, Rahman MA, Philip A, Lewin AH, Kopajtic TA, Kuhar MJ. [125I]RTI-55: a potent ligand for dopamine transporters. European Journal of Pharmacology. 1991 Feb 26;194(1):133-4.
  2. Weed MR, Mackevicius AS, Kebabian J, Woolverton WL. Reinforcing and discriminative stimulus effects of beta-CIT in rhesus monkeys. Pharmacology, Biochemistry and Behaviour. 1995 Aug;51(4):953-6.
  3. Shaya EK, Scheffel U, Dannals RF, Ricaurte GA, Carroll FI, Wagner HN Jr, Kuhar MJ, Wong DF (1992). "In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55". Synapse. 10 (2): 169–172. doi:10.1002/syn.890100210.  Unknown parameter |month= ignored (help)
  4. Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, Seibyl JP, Rogers JF (2007). "Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study". Journal of Clinical Psychopharmacology. 27 (1): 71–75. PMID 17224717.  Unknown parameter |monht= ignored (help)
  5. Staffen W, Mair A, Unterrainer J, Trinka E, Bsteh C, Ladurner G. [123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nuclear Medicine Communications. 2000 May;21(5):417-24.
  6. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. Journal of Nuclear Medicine. 2007 Jun;48(6):857-64.
  7. Seppi K, Scherfler C, Donnemiller E, Virgolini I, Schocke MF, Goebel G, Mair KJ, Boesch S, Brenneis C, Wenning GK, Poewe W. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Archives of Neurology. 2006 Aug;63(8):1154-60.



Linked-in.jpg